Integración de la Medicina Biorreguladora de Sistemas durante quimioterapia standard basada en bleomicina, etopósido y platino, en cáncer testicular metastásico. Reporte de un caso.
AbstractIntroduction: Metastatic testicular germ cell tumors are potentially curable with cisplatin-based chemotherapy. Evidence regarding systems bioregulatory medicine (SBM) as supportive care during BEP chemotherapy is limited. This report describes its incorporation into the management of a single case, without establishing antitumor efficacy or a causal effect on treatment tolerability.Case presentation: A 34-year-old man had a mixed germ cell tumor of the left testis, pathological category pT2, with lymphovascular invasion, retroperitoneal lymphadenopathy, and bilateral pulmonary nodules consistent with metastatic disease. The prechemotherapy alpha-fetoprotein (AFP) level was 44.4 ng/mL. Clinical stage III was documented.Intervention: Four cycles of bleomycin, etoposide, and cisplatin (BEP) chemotherapy were documented, starting on December 2 and 30, 2024, January 27, 2025, and February 24, 2025, at institutional 28-day intervals. No additional delays, dose omissions, or dose reductions due to toxicity were recorded. Systems bioregulatory medicine (SBM) was administered before, during, and after chemotherapy as complementary supportive care.Results: AFP levels decreased to 10.7, 1.13, and 1.00 ng/mL before the second, third, and fourth cycles, respectively, and measured 1.63 ng/mL in September 2025. The highest documented toxicity was grade 1 according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. ECOG performance status remained at 0, and Karnofsky performance status ranged from 90% to 100%. Post-treatment assessment on May 6, 2025, showed resolution of the pulmonary and nodal lesions, with no pathological metabolic activity on PET/CT.Conclusion: Adherence to the institutional treatment schedule, mild toxicity, and a favorable response were observed during BEP chemotherapy with conventional supportive care and SBM. The single-case design and modified treatment schedule preclude attributing these outcomes to the complementary intervention or establishing the absence of pharmacological interactions.
Authors
- Carmen Rivas (ORCID: https://orcid.org/0000-0002-0518-7199)
- Luis Martínez (ORCID: https://orcid.org/0000-0002-6297-1449)
- Paula Martínez
Publication Details
- Journal
- Figshare
- Published
- 2026-11-12
- DOI
- https://doi.org/10.6084/m9.figshare.34988941
- Primary Topic
- Complementary and Alternative Medicine Studies
- Type
- preprint